Common Contracts
2 similar Voting Agreement contracts by Caribou Biosciences, Inc.
FIRST AMENDMENT TO THIRD AMENDED AND RESTATED VOTING AGREEMENTVoting Agreement • July 1st, 2021 • Caribou Biosciences, Inc. • Biological products, (no disgnostic substances) • Delaware
This First Amendment to Third Amended and Restated Voting Agreement (this “Amendment”), effective as of March 29, 2021, is made by and among Caribou Biosciences, Inc., a Delaware corporation (the “Company”), PFM Health Sciences, LP and certain stockholders of the Company with reference to that certain Third Amended and Restated Voting Agreement dated as of March 2, 2021 (the “Voting Agreement”) by and among the holders of the Company’s Series A Preferred Stock, $0.0001 par value per share (“Series A Preferred Stock”), the holders of the Company’s Series A-1 Preferred Stock, $0.0001 par value per share (“Series A-1 Preferred Stock”), the holders of the Company’s Series B Preferred Stock, $0.0001 par value per share (the “Series B Preferred Stock”), the holders of the Company’s Series C Preferred Stock, $0.0001 par value per share (the “Series C Preferred Stock;” and referred to herein collectively with the Series A Preferred Stock, the Series A-1 Preferred Stock, and the Series B Prefer
FIRST AMENDMENT TO THIRD AMENDED AND RESTATED VOTING AGREEMENTVoting Agreement • May 7th, 2021 • Caribou Biosciences, Inc. • Biological products, (no disgnostic substances) • Delaware
This First Amendment to Third Amended and Restated Voting Agreement (this “Amendment”), effective as of March 29, 2021, is made by and among Caribou Biosciences, Inc., a Delaware corporation (the “Company”), PFM Health Sciences, LP and certain stockholders of the Company with reference to that certain Third Amended and Restated Voting Agreement dated as of March 2, 2021 (the “Voting Agreement”) by and among the holders of the Company’s Series A Preferred Stock, $0.0001 par value per share (“Series A Preferred Stock”), the holders of the Company’s Series A-1 Preferred Stock, $0.0001 par value per share (“Series A-1 Preferred Stock”), the holders of the Company’s Series B Preferred Stock, $0.0001 par value per share (the “Series B Preferred Stock”), the holders of the Company’s Series C Preferred Stock, $0.0001 par value per share (the “Series C Preferred Stock;” and referred to herein collectively with the Series A Preferred Stock, the Series A-1 Preferred Stock, and the Series B Prefer
